Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Interim Trial Data ‘Very Exciting,’ Gloucester Says
RxTrials Institute Drug Pipeline Alert
Dec. 17, 2008 | Vol. 6 No. 51
Interim Trial Data ‘Very Exciting,’ Gloucester Says
Gloucester Pharmaceuticals received positive interim results from a Phase I/II combination study of romidepsin in patients with relapsed or refractory multiple myeloma.
The study is an open-label, single-center, single-arm, dose-escalating trial of romidepsin in combination with Velcade (bortezomib) and dexamethasone followed by maintenance romidepsin therapy until disease progression. Patients who received the combination had an overall response rate of 85 percent, Gloucester said.
Romidepsin is being investigated as a treatment for hematologic malignancies. “While romidepsin has demonstrated significant single-agent activity in other difficult to treat cancers, the high response rates observed in this combination study in a relapsed or refractory patient population are very exciting,” the company said in a statement.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.